Clostridium difficile infection
prevention of primary and recurrent CDI through companion probiotics
Resilience Enforcement and Competitive Intestinal Pathogen Exclusion
CDI has become the leading cause of nosocomial infections worldwide over the last decade. Control measures (hygiene and reduced use of antibiotics) in hospitals have proven capable of lowering incidence by up to 80% but insufficient to prevent CDI. GeneCreek has discovered specific bacterial species which are naturally present in the intestines of healthy subjects, protect against CDI.
CDI is essentially triggered by prescription of antibiotics. Targeted preventive use of a probiotics product for inpatients receiving antibiotics represents a latent market in the order of €100M in the EU. The design of an innovative companion probiotics product resulting from this discovery is the subject of a pending patent application with high potential to deliver broad protection. The company is working with EU food business operators (FBOs) specializing in probiotics to transform the design into a quality CDI prevention product, disrupting the market. Time-to-market is estimated at 2 years.
prevention and improved therapeutic outcome through use of probiotics
Epidemiology. CRC is a multi-factorial disease resulting from lifestyle, genetic, and environmental factors. Almost half of the population will develop at least one benign adenomatous colonic polyp during life, with less than 3% of those cases going on to develop CRC. Because symptoms are rare until very late stages, most cases go undetected. The 5-year survival expectation for CRC patients ranges from 93% for early stages to 8% in fully advanced stages. In the US, over 130,000 new CRC cases are declared and the annual death toll approaches 50,000 which makes it the third deadliest cancer type after lung and prostate/breast cancer.
prevention during pregnancy and infancy though food supplements
Etiology. About 30% of children with food allergies are allergic to multiple food allergens, and pediatric allergies as a whole are interrelated. A frequent sequential allergy development pattern referred to as the "allergic march" starts with infant eczema, then toddler food allergies, then school aged asthma and hay fever. Immune system maturation happens during the first two years of life and sets the stage for this march.
Economics. Familial aggregation of food allergy is important. U.S. families spend $3,500 per child and $20B annually caring for children with food allergies, whereas willingness-to-pay of parents for symptom relief of eczema was estimated at $2.6B. The food intolerance market is expected to reach $14B by 2022. The market for food supplements effective to prevent or stop the pediatric allergic march is a latent niche, since dedicated and scientifically proven products are not yet available. GeneCreek has obtained indications that a curative positioning is possible as well. The allergy immunotherapy (AIT) market is expected to reach $4.3B by 2023.